Our data suggest a need for clinical trials of ALK inhibitors in combination with downstream pathway inhibitors to enhance the antitumor activity of the former compounds, in particular, their ability to overcome the resistance of ALKF1174L–mutated NB cells to crizotinib. This evidence concerns the gene ALK and neuroblastoma.